The Norwegian oncology developer BerGenBio ASA is making an initial public offering of its shares on the Oslo Stock Exchange in order to support development of a Phase 2 compound targeting three cancer indications.
Adaptimmune Therapeutics Plc has raised $61.8 million, net of expenses, in a public offering of its American Depositary Shares (ADSs) to advance its T cell receptor products for cancer.
Cell Medica Ltd has closed a £60 million Series C financing round to support its cell therapy platforms. The financing was announced not long after the company received a fast track designation from the US Food and Drug Administration for its lead oncology product baltaleucel-T.
One of the biggest European Series A financings so far this year has been arranged by venture capitalists for a new company with technology to treat patients with lung transplants who are at risk of dying because of a condition known as bronchiolitis obliterans syndrome (BOS).
A research collaboration dating from 2015 has yielded a licensing agreement for Argenx NV of Belgium. The deal involves an antibody targeted ApoC3, a protein involved in dyslipidemia, a disorder caused by an abnormal amount of lipids in the blood.
Congenica Ltd has raised £8 million in a Series B financing round to support the expanded marketing of its technology for analysing genome-scale DNA data. Known as Sapientia, the platform produces diagnostic reports that can be linked to symptoms patients show for genetic diseases.
Lead Pharma Holding BV has reported progress in its collaboration with Sanofi SA to develop new medicines for autoimmune diseases. A second milestone, the size of which was not disclosed, has been paid to the Dutch company by its Big Pharma partner.
Sweden-based venture capital fund HealthCap has provided funds to a new company that is developing alpha-particle emitting radiotherapeutics for cancer. Fusion Pharmaceuticals of Canada has raised $25 million in a Series A financing round.
The language was assertive, almost combative. Four venture capitalists were asked to give their views of the environment for biotech investment in Europe and they each spoke about the need to identify good assets early, while jettisoning those with less promise.
Novo A/S, the holding company for the Danish diabetes and enzymes empire, has invested €90.3 million in Evotec AG, the German research service and product development company.